Health Care — Alle selskaper

Walvax Biotechnology Co Ltd

The company maintains a strong liquidity position with a current ratio of 2.35, indicating sufficient short-term assets to cover liabilities. However, its free cash flow is negative at -4.1 million…

Chengdu Kanghua Biological Products Co Ltd

Chengdu Kanghua Biological Products Co Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.04, indicating a low reliance on debt financing. The company's liquidity position is…

Beijing Tong Ren Tang Chinese Medicine Co Ltd

The company maintains a strong liquidity position, with a current ratio of 19.65 and cash and equivalents amounting to HKD 2.23 billion, which significantly exceeds its total liabilities of HKD 472…

4169.Tw

The company maintains a strong liquidity position, with a current ratio of 7.47, indicating a high ability to meet short-term obligations. However, the company has a negative net cash position afte…

SanBio Co Ltd

SanBio maintains a strong liquidity position, with cash and equivalents amounting to ¥15,083.23 million, significantly exceeding its total liabilities of ¥2,016.87 million. The company's liquidity…

4771.Tw

The company maintains a market price of 199.5 TWD, with a market capitalization of 11,676,336,000 TWD. Its price-to-earnings ratio is 15.76, and the price-to-book ratio is 2.93, indicating a modera…

Perseus Proteomics Inc

Perseus Proteomics Inc has a strong liquidity position, with cash and equivalents amounting to ¥15.41 billion, representing 91.1% of total assets. The company has no long-term debt and a current ra…

494120.Kq

The company maintains a strong liquidity position, with a current ratio of 8.8, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 23,670…

Suzhou Ribo Life Science Co Ltd

Structure and Liquidity Suzhou Ribo Life Science Co Ltd exhibits a negative total equity of CNY -93.94 million and a debt-to-equity ratio of -5.86, indicating a leveraged capital structure with lia…

StemCell Institute Inc

StemCell Institute Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥2.85 billion, significantly exceeding its total liabilities of ¥3.85 billion, resulting in a cu…

7743.T

The company's capital structure is characterized by a debt-to-equity ratio of 1.45, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…

Darwin AG

The company maintains a strong liquidity position, with a current ratio of 4.05 and cash and equivalents amounting to 20.66 million EUR. The low debt-to-equity ratio of 0.03 indicates a conservativ…

950160.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. Its liquidity position is weak, with a current ratio of 0.24, s…

AbL Diagnostics SA

AbL Diagnostics SA has a debt-to-equity ratio of 0.34, indicating a relatively conservative capital structure with a strong equity base. The company's current ratio of 3.01 suggests it has sufficie…

Adagio Medical Holdings Inc

The company's capital structure is highly leveraged, with total liabilities of $61.8 million and total equity of -$53.7 million, resulting in a debt-to-equity ratio of -0.91. Liquidity is constrain…

Addus Homecare Corp

Addus Homecare Corp maintains a conservative capital structure characterized by low leverage and strong equity backing. The company reports total assets of $1.44 billion against total liabilities o…

Aeon Biopharma Inc

Aeon Biopharma Inc exhibits a capital structure with a negative total equity of $27.95 million and a debt-to-equity ratio of -0.48, indicating a leveraged position with more liabilities than equity…

Rocket Doctor AI Inc

Rocket Doctor AI Inc has a current ratio of 1.8, indicating moderate liquidity, but its operating cash flow of -841,000 CAD suggests ongoing cash outflows from operations. The company's debt-to-equ…

Advicenne

The company's capital structure is characterized by a negative operating cash flow of $3.727 billion, indicating a cash outflow from operations, which may signal financial stress or heavy investmen…

Althx.Pa

The company's capital structure is characterized by a negative equity position of -1,656,910 EUR and a debt-to-equity ratio of -1.73, indicating a significant reliance on debt financing. The liquid…

Arecor Therapeutics PLC

AREC.L maintains a strong liquidity position with a current ratio of 4.78, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company report…

Bangkok Genomics Innovation PCL

The company maintains a strong liquidity position, with cash and equivalents amounting to 359.15 million THB, significantly exceeding its total liabilities of 52.36 million THB. The current ratio o…

Cogstate Ltd

CGS.AX maintains a strong liquidity position with a current ratio of 3.77 and a low debt-to-equity ratio of 0.01, indicating minimal leverage and a robust balance sheet. The company holds $23.19 mi…

Entera Bio Ltd

Entera Bio operates with a market capitalization of $71.87 million and a price-to-book ratio of 5.49, indicating a premium valuation relative to its tangible book value. The company holds $7.11 mil…

Earth Science Tech Inc

Earth Science Tech Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.04, indicating minimal leverage. The company's liquidity position is assessed as medium, with a cu…

Evaxion A/S

Evaxion maintains a capital structure with no debt, as indicated by a debt-to-equity ratio of 0.0, and a total equity of $2.6 million. The company's liquidity position is unclear due to the absence…

Fonar Corp

Fonar Corp maintains a strong liquidity position with $56.33 million in cash and equivalents, representing 25.97% of total assets, and a current ratio of 8.45, well above the industry median of 2.1…

Genovis AB

Genovis AB maintains a strong liquidity position, with a current ratio of 9.59 and cash and equivalents amounting to 135.81 million SEK, which significantly exceeds its total liabilities of 95.80 m…

Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals Inc maintains a strong liquidity position, with a current ratio of 21.02 and cash and equivalents of $31.28 million, which significantly exceeds its total liabilities of $7.54…

Krys.O

KRYSTAL Biotech maintains a strong liquidity position, with a current ratio of 9.95 and $496.3 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The compa…

Little Green Pharma Ltd

Little Green Pharma Ltd has a market capitalization of AUD 26.61 million, with a current market price of AUD 0.087 per share. The company has 305.86 million shares outstanding, with no dilution fro…

Lunai Bioworks Inc

Lunai Bioworks Inc has a market capitalization of $10.03 million and a price-to-book ratio of 0.08, indicating a significant discount to its book value. The company's liquidity position is weak, wi…

Lantern Pharma Inc

Lantern Pharma operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company's liquidity position is strong, with a cu…

Hospital Mater Dei SA

Hospital Mater Dei SA has a market price of 5.12 BRL and a market cap of 1,699,314,816 BRL, with a price-to-book ratio of 1.09 and a price-to-tangible-book ratio of 1.09. The company's enterprise v…

MiniMed Group Inc

MiniMed Group Inc has an analyst mean price target of 10.77 EGP, with a median price target of 10.77 EGP, indicating a relatively narrow range of expectations among analysts. The high and low price…

Molecure SA

Molecure SA maintains a strong liquidity position, with a current ratio of 5.79, indicating the company can easily cover its short-term liabilities with its current assets. The company holds PLN 17…

Mayne Pharma Group Ltd

Mayne Pharma Group Ltd has a market capitalization of 201,489,650.96 AUD, with a current market price of 2.48 AUD per share. The company has 81,245,827 basic and diluted shares outstanding, indicat…

Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc maintains a strong liquidity position, with $14.21 million in cash and equivalents, representing 49.7% of total assets. The company's liquidity FPT (free cash flow to tot…

Nsci.V

NSCI.V has a market price of 0.135 CAD and a market cap of 18,691,334.69 CAD, with a price-to-book ratio of 1.39 and a price-to-tangible-book ratio of 1.39. The company's enterprise value to EBITDA…

Perimeter Medical Imaging AI Inc

Perimeter Medical Imaging AI Inc has a current ratio of 4.07, indicating strong short-term liquidity, but its operating cash flow of -$3.57 million and free cash flow of -$1.97 million suggest ongo…

Radiopharm Theranostics Ltd

Radiopharm Theranostics has a market capitalization of AUD 55.88 million with a current share price of AUD 4.73, implying a 298% discount to the mean analyst price target of AUD 14.38. The company…

Rx.V

RX.V maintains a strong liquidity position, with a current ratio of 5.51, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidity_fpt sco…

Scpp.Wa

SCPP.WA has a current ratio of 13.06, indicating strong short-term liquidity, but its free cash flow is negative at -57.62 million PLN, suggesting ongoing cash outflows from operations. The company…

Sikarin PCL

Sikarin maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a conservative leverage position relative to the industry median of 0.15. The company's liquidity is ass…

Sunway Healthcare Holdings Bhd

Sunway Healthcare Holdings Bhd has a debt-to-equity ratio of 0.64, indicating a moderate level of leverage, and a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company…

Tetratherix Ltd

Tetratherix operates with a fully diluted share count of 50.77 million shares, with no additional shares outstanding in the diluted scenario, indicating no immediate dilution risk from stock option…

Tvardi Therapeutics Inc

Tvardi Therapeutics operates with a high liquidity position, as evidenced by $49.24 million in cash and equivalents, which significantly exceeds its total liabilities of $60.90 million, resulting i…

Vivoryon Therapeutics NV

Vivoryon Therapeutics has a market capitalization of EUR 37.31 million, with a current market price of EUR 1.26 per share. The company holds EUR 22.00 million in cash and equivalents, indicating a…

Samsung Epis Holdings Co Ltd

Samsung Epis Holdings Co Ltd has a basic and diluted share count of 24,883,049 shares outstanding, indicating no dilution from potential share issuance. However, liquidity risk could not be assesse…

Oscotec Inc

Oscotec Inc maintains a strong capital structure with a debt-to-equity ratio of 0.09, indicating a conservative leverage position relative to its equity base. The company's liquidity position is ch…

Panion & BF Biotech Inc

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.33, well below the industry median of 0.65. However, its liquidity position is constrained by negative net ca…

Laekna Inc

Laekna Inc's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative approach to financing. However, the company's liquidity position is rated as medium,…

Shanghai Fosun Pharmaceutical Group Co Ltd

Shanghai Fosun Pharmaceutical Group Co Ltd has a capital structure with 540,971,500 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or…

228850.Kq

The company maintains a strong liquidity position, with a current ratio of 14.95, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 47.5…

Huons Co Ltd

Huons maintains a conservative capital structure with a debt-to-equity ratio of 0.42, below the median for the pharmaceutical industry, and holds KRW 49.13 billion in cash and equivalents. However,…

2500.Hk

The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position. Its liquidity position is strong, with a current ratio of 2.77 a…

Beijing Biostar Pharmaceuticals Co Ltd

The company has a market capitalization of 1.53 billion CNY, with a market price of 4.2 CNY per share. The shares outstanding are 364,588,000 for both basic and diluted shares, indicating no diluti…

Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group's capital structure and liquidity position are not fully assessable due to the absence of balance-sheet inputs and no going-concern language in the source documents. The…

6099.T

The company maintains a strong liquidity position, with a current ratio of 1.68 and a significant cash and equivalents balance of 6,845,410,000 JPY. The price-to-book ratio of 2.92 and a low debt-t…

6446.Tw

The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 6.2,…

Tanvex BioPharma Inc

Tanvex BioPharma Inc has a price-to-book ratio of 25.0 and a price-to-tangible-book ratio of 25.0, indicating a high valuation relative to its equity base. The company's liquidity position is chara…

TSH Biopharm Corp Ltd

TSH Biopharm Corp Ltd maintains a strong liquidity position, with a current ratio of 6.27 and cash and equivalents amounting to 464.54 million TWD. The company's low debt-to-equity ratio of 0.01 in…

Aso International Inc

Aso International Inc maintains a strong liquidity position, with a current ratio of 7.01, indicating a high ability to meet short-term obligations. The company holds JPY 1,873,428,000 in cash and…

Alf Meem Yaa for Medical Supplies and Equipment Company SJSC

The company maintains a strong liquidity position with a current ratio of 3.28, indicating that it has more than three times the current assets to cover its current liabilities. However, its operat…

Bausch Health Companies Inc

Bausch Health Companies Inc exhibits a distressed capital structure characterized by negative total equity of -554 million USD and long-term debt of 20.85 billion USD. The debt-to-equity ratio stan…

Biovica International AB

Biovica's capital structure is characterized by a high proportion of equity, with total equity of 96.64 million SEK and long-term debt of 7.83 million SEK, resulting in a debt-to-equity ratio of 0.…

Bioventix PLC

BVXP.L maintains a strong liquidity position, with a current ratio of 9.17, indicating that the company has significantly more current assets than current liabilities. The company has no long-term…

Cleopatra Hospital SAE

Cleopatra Hospital SAE has a liquidity ratio of 1.36, indicating a moderate level of liquidity. The company's price-to-book ratio is 3.93, which is relatively high, suggesting that the market is va…

Demant.Co

Demant maintains a capital structure with a debt-to-equity ratio of 2.13, indicating a relatively high leverage position compared to industry norms. The company's liquidity is assessed as medium, w…

Desn.S

Desn maintains a strong liquidity position, with a current ratio of 2.67 and CHF 147.77 million in cash and equivalents, which supports its short-term obligations. The company's debt-to-equity rati…

Euroapi SA

Euroapi's capital structure is characterized by a lack of detailed liquidity metrics, as liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern languag…

Gpth.Ns

GPTH.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.14, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, wit…

Guerbet SA

Guerbet's capital structure is characterized by a lack of dilution risk, as the number of basic and diluted shares outstanding is identical at 12.6 million shares. However, liquidity risk could not…

Lenskart Solutions Ltd

Lenskart Solutions Ltd maintains a debt-to-equity ratio of 0.42, indicating a relatively conservative capital structure. The company's liquidity position is characterized as medium, with a current…

Medline Inc

Medline Inc's capital structure and liquidity position are characterized by a high price-to-earnings ratio of 202.62, indicating a premium valuation relative to its earnings. The company's market c…

Ose Immunotherapeutics

OSE.PA has a negative operating cash flow of -34 million EUR and a net loss of -37.4 million EUR, indicating significant liquidity and profitability challenges. The company's liquidity risk could n…

OssDsign AB

OssDsign AB has a market capitalization of 459.1 million SEK and a price-to-book ratio of 2.04, indicating that the market values the company at a premium to its book value. The company's liquidity…

Qia.De

The company maintains a strong liquidity position, with a current ratio of 3.9, indicating a robust ability to meet short-term obligations. However, the company has a net cash position that is nega…

Biofarm SA

ROBIO.BX maintains a strong liquidity position, with a current ratio of 4.95, indicating the company has nearly five times more current assets than current liabilities. The company holds RON 111.75…

Rua Life Sciences PLC

RUA.L's capital structure is characterized by a debt-to-equity ratio of 0.11, indicating a relatively low level of leverage. The company's liquidity position is reflected in a current ratio of 4.64…

Sann.S

SANN.S has a negative equity position of CHF -11.82 million and a debt-to-equity ratio of -1.37, indicating a leveraged capital structure with liabilities exceeding equity. The company holds CHF 22…

SenzaGen AB

SenzaGen operates with a relatively strong liquidity position, as evidenced by a current ratio of 2.26 and cash and equivalents of 26.78 million SEK. However, the company reported negative operatin…

Selvita SA

Selvita's capital structure is characterized by a debt-to-equity ratio of 0.53, indicating a moderate level of leverage. The company's liquidity position is reflected in a current ratio of 1.04, su…

Sanofi SA

Sanofi's capital structure and liquidity position are characterized by a market capitalization of €112.66 billion, with a market price of €46.65 per share. The company has 2.415 billion shares outs…

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc maintains a strong liquidity position, with $30.15 million in cash and equivalents, representing 64% of total assets. The company's liquidity FPT (free cash flow to tota…

JW Pharmaceutical Corp

JW Pharmaceutical Corp maintains a strong liquidity position, with a current ratio of 1.42 and free cash flow of 28,987,163,230 KRW, indicating the company can meet short-term obligations and fund…

MicroPort NeuroScientific Corp

MicroPort NeuroScientific Corp maintains a strong liquidity position, with a current ratio of 6.01 and cash and equivalents amounting to CNY 611.25 million, which represents 29% of total assets. Th…

Lepu Scientech Medical Technology Shanghai Co Ltd

Lepu Scientech has a market capitalization of 3.93 billion CNY, with a current market price of 11.34 CNY per share. The company has 346.75 million shares outstanding, with no dilution from preferre…

EUCALIA Inc

EUCALIA Inc has a market price of 685.0 JPY and a market capitalization of 24,474,296,500 JPY, with a price-to-earnings ratio of 8.81 and a price-to-book ratio of 1.19. The company's liquidity posi…

INKON Life Technology Co Ltd

INKON Life Technology Co Ltd has a market capitalization of 7.79 billion CNY and a price-to-earnings ratio of 113.61, significantly above the industry median for pharmaceutical and healthcare servi…

T&L Co Ltd

T&L Co Ltd maintains a strong liquidity position, with a current ratio of 4.22 and cash and equivalents of KRW 9,178,746,320, indicating a solid ability to meet short-term obligations. The company'…

Rohto Pharmaceutical Co Ltd

Rohto maintains a strong liquidity position with a current ratio of 2.3 and cash and equivalents of ¥77.16 billion, which supports operational flexibility and debt servicing. The company's liquidit…

ASKA Pharmaceutical Holdings Co Ltd

The company maintains a strong liquidity position, with a current ratio of 2.66 and cash and equivalents amounting to ¥12.02 billion. Its debt-to-equity ratio is 0.13, indicating a conservative cap…

Japan Animal Referral Medical Center Co Ltd

Japan Animal Referral Medical Center Co Ltd maintains a liquidity position with a current ratio of 1.16, indicating a moderate ability to meet short-term obligations. The company's liquidity_fpt me…

7775.T

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2,995,993,000, which is supported by a current ratio of 2.47. This indicates the company has sufficient sh…

Adoc.Pa

Alpa.Kl

ALPA.KL maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio o…

Arcoma AB

Arcoma maintains a strong liquidity position with a current ratio of 3.49 and no long-term debt, indicating a conservative capital structure. The company's liquidity risk is assessed as low, suppor…

Aurx.Pk

AURX.PK exhibits a negative equity position of -$956,560, indicating a significant financial challenge, and a debt-to-equity ratio of -0.52, which suggests the company is leveraging debt to fund op…

Bmhs.Jk

BMHS.JK has a market price of 185.00 IDR, with a market capitalization of 1,591,631,992,560.00 IDR. The company's price-to-earnings ratio is 128.16, and its price-to-book ratio is 0.82, indicating…

Celularity Inc

Celularity operates with a negative total equity of -$38.06 million and a cash and equivalents balance of $6.18 million, indicating a liquidity risk as its cash reserves are insufficient to cover i…

Detection Technology Oyj

Detection Technology Oyj maintains a strong liquidity position, with a current ratio of 3.44 and cash and equivalents of EUR 24.98 million, which supports its short-term obligations. The company's…

Insight Molecular Diagnostics Inc

The company's capital structure shows a negative equity position of $31.5 million and a current ratio of 1.27, indicating limited short-term liquidity coverage. With $11.6 million in cash and $10.6…

Ime.Ax

IME.AX operates with a current liquidity position that is characterized by a debt-to-equity ratio of 0.04 and a current ratio of 1.73, indicating a relatively strong short-term liquidity position.…

Mbx.To

MBX.TO has a market capitalization of CAD 38.65 million and a price-to-book ratio of 1.39, indicating that the market values the company at a premium to its book value. The company's liquidity posi…

MiMedx Group Inc

MiMedx maintains a strong liquidity position with $166.1 million in cash and equivalents, representing 48.5% of total assets, and a current ratio of 4.32, well above the industry median of 1.8. The…

Mesa Laboratories Inc

Mesa Laboratories has a market price of $96.47, yielding a market cap of $532.98 million and a price-to-book ratio of 3.33. The company's liquidity position is characterized by $27.32 million in ca…

MindMaze Therapeutics Holding SA

MMTX.S exhibits a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a purely equity-funded operation. The company holds CHF 9.47 million in cash and equivalents…

Mereo BioPharma Group PLC

Mereo BioPharma Group PLC maintains a strong liquidity position, with cash and equivalents amounting to $40.99 million, representing 90% of its total assets. The company has no long-term debt, and…

Nanoform Finland Oyj

The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. With 24.002 million euros in cash and equivalents, the company ma…

NanoViricides, Inc

NanoViricides, Inc has a market capitalization of $37.58 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company at a premium to its book value. The company has…

Oncoinvent ASA

Oncoinvent ASA maintains a strong liquidity position, with cash and equivalents amounting to NOK 177.6 million, significantly exceeding its total liabilities of NOK 58.6 million, resulting in a cur…

Pharming Group NV

Pharming Group has a market capitalization of $926.2 million, with a current market price of $13.2 per share. The company has 70.17 million shares outstanding, with no dilution from potential share…

Prelude Therapeutics Inc

Prelude Therapeutics operates with a market capitalization of $371.5 million and a price-to-book ratio of 5.41, indicating a premium valuation relative to its book value. The company holds $35.3 mi…

Prokidney Corp

Prokidney Corp has a negative net income of $68.99 million and a negative total equity of $1.01 billion, indicating significant financial distress. The company's liquidity position is weak, with a…

Quantum Biopharma Ltd

Quantum Biopharma operates with a current liquidity position of $1.91 million in cash and equivalents, while its total liabilities amount to $4.24 million. The company's liquidity FPT (free cash fl…

Stratec SE

SBSG.DE has a debt-to-equity ratio of 0.56, indicating a moderate level of leverage, and a current ratio of 3.97, suggesting strong short-term liquidity. However, the company reported negative oper…

Sernova Biotherapeutics Inc

Sernova operates with a negative equity position of CAD -5.5 million and a current ratio of 0.62, indicating a liquidity risk as the company holds more liabilities than current assets. The company'…

Svas Biosana S.P.A.

SVSB.MI has a debt-to-equity ratio of 0.55, indicating a moderate level of leverage relative to its equity base. The company's liquidity is assessed as medium, with a key flag noting that net cash…

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc maintains a strong liquidity position, with cash and equivalents amounting to $217.05 million, significantly exceeding its total liabilities of $104.17 million, resulting in…

Gushengtang Holdings Ltd

Gushengtang Holdings Ltd has a market capitalization of 6.02 billion CNY, with a current market price of 26.36 CNY per share. The company's shares are fully diluted, with no additional shares outst…

Boji Medical Technology Co Ltd

Boji Medical Technology Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.05, indicating minimal leverage. The company's liquidity position is characterized as med…

Daito Pharmaceutical Co Ltd

Daito Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.23, indicating limited leverage and a strong equity base. The company's liquidity position is charac…

9229.T

The company's capital structure is characterized by a high debt-to-equity ratio of 2.61, indicating a significant reliance on debt financing. The liquidity position is moderate, with a current rati…

Acl.Ax

ACL.AX maintains a capital structure with a debt-to-equity ratio of 1.69, indicating a significant reliance on debt financing. The company's liquidity position is characterized by a current ratio o…

Agomab Therapeutics NV

(a) Capital structure and liquidity cannot be quantitatively assessed due to the absence of balance-sheet inputs in the available data. The risk assessment explicitly notes that liquidity risk coul…

Ekh.Bk

EKH.BK's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio o…

MustGrow Biologics Corp

MustGrow Biologics Corp maintains a strong liquidity position with CAD 5.89 million in cash and equivalents, significantly exceeding its total liabilities of CAD 1.33 million, resulting in a curren…

NervGen Pharma Corp

NervGen Pharma Corp maintains a strong liquidity position, with cash and equivalents amounting to CAD 26.56 million, significantly exceeding its total liabilities of CAD 15.40 million, resulting in…

Nurexone Biologic Inc

Nurexone Biologic Inc maintains a strong liquidity position, with a current ratio of 10.16 and cash and equivalents of $3.26 million, significantly exceeding liabilities of $511,000. The company's…

Hydreight Technologies Inc

Hydreight Technologies Inc has a debt-to-equity ratio of 0.42, indicating a relatively conservative capital structure with equity financing playing a larger role than debt. The company reported neg…

Neurizon Therapeutics Ltd

Neurizon Therapeutics Ltd operates with a fully diluted share count of 746,274,115 shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk fro…

Jayamas Medica Industri TBK PT

Jayamas Medica Industri TBK PT maintains a strong liquidity position, with a current ratio of 10.36 and cash and equivalents amounting to 541.8 billion IDR. The company's debt-to-equity ratio is 0.…

Prodia Widyahusada Tbk PT

The company maintains a strong liquidity position, with a current ratio of 6.13, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 110 b…

Pentixapharm Holding AG

The company's capital structure is characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations, and a current ratio of 1.73, suggesting adequate short-term liquidity to…

Substrate Artificial Inteligence SA

Substrate Artificial Intelligence SA has a basic and diluted share count of 111,437,057 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible in…

Inspecs Group PLC

SPECI.L has a debt-to-equity ratio of 0.63, indicating a moderate level of leverage, and a current ratio of 1.42, suggesting it has sufficient short-term assets to cover its short-term liabilities.…

Taro.Ns

TARO.NS maintains a debt-to-equity ratio of 0.54, indicating a moderate level of leverage, and a current ratio of 1.38, suggesting adequate short-term liquidity to cover its obligations. However, t…

Xtant Medical Holdings Inc

Xtant Medical maintains a conservative capital structure with $17.05 million in cash and equivalents and $25.43 million in long-term debt, resulting in a debt-to-equity ratio of 0.5 and a current r…

Daewoong Co Ltd

Daewoong maintains a capital structure with a debt-to-equity ratio of 0.57, indicating moderate leverage. The company's liquidity position is characterized by a current ratio of 1.33, suggesting it…

Shinpoong Pharmaceutical Co Ltd

Shinpoong Pharmaceutical maintains a strong liquidity position, with a current ratio of 2.8 and cash and equivalents of 47.95 billion KRW, which supports its short-term obligations. The company's l…

Korea United Pharm Inc

Korea United Pharm Inc maintains a strong liquidity position, with a current ratio of 5.63 and cash and equivalents of 40,270.45 billion KRW. The company's debt-to-equity ratio is 0.03, indicating…

Microport Cardioflow Medtech Corp

Microport Cardioflow Medtech Corp has a fully diluted share count of 1,273,311,439, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options o…

223250.Kq

The company maintains a strong liquidity position, with a current ratio of 1.08 and cash and equivalents amounting to 22,309,534,260 KRW. Its debt-to-equity ratio is 0.22, indicating a relatively c…

GenFleet Therapeutics (Shanghai) Inc

GenFleet Therapeutics (Shanghai) Inc has a basic and diluted share count of 370,366,630, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed…

Shanghai Bao Pharmaceuticals Co Ltd

Shanghai Bao Pharmaceuticals Co Ltd has a market capitalization of 8.13 billion CNY, with a market price of 24.94 CNY per share. The company has no dilution risk, as the number of basic and diluted…

Anhui Sunhere Pharmaceutical Excipients Co Ltd

The company maintains a market price of 12.55 CNY, with a market capitalization of 2.94 billion CNY. Its price-to-earnings ratio is 16.67, and its price-to-book ratio is 2.92, indicating a moderate…

Jiangxi Sanxin Medtec Co Ltd

Jiangxi Sanxin Medtec maintains a price-to-book ratio of 3.75 and a price-to-tangible-book ratio of 3.75, indicating a premium valuation relative to its equity base. The company's liquidity positio…

600085.Ss

The company maintains a relatively strong liquidity position, with a current ratio of 3.59, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the liq…

Arrail Group Ltd

Arrail Group Ltd has a market capitalization of CNY 1.03 billion, with a current market price of CNY 1.83 per share. The company has no dilution risk, as the number of basic and diluted shares outs…